StockData
ProQR Therapeutics N.V. logo

ProQR Therapeutics N.V. (PRQR) stock

PRQRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026Score 7/30
$1.15−0.03 (-2.54%)

Close on Nov 17, 2026Market cap $121.17MP/E –Yield –

ProQR Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

ProQR Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -228.9%. For fiscal 2025 it was -265.2%, against -146.9% the year before. The highest annual figure on record is -146.9% in fiscal 2024.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-265.2%−118.4
FY2024Dec 31, 2024-146.9%+284.8
FY2023Dec 31, 2023-431.7%+1360.9
FY2022Dec 31, 2022-1792.5%+2757.3
FY2021Dec 31, 2021-4549.8%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-99.6%+219.4
Q1 FY2026Mar 31, 2026-658.3%−435.3
Q4 FY2025Dec 31, 2025-190.3%+25.8
Q3 FY2025Sep 30, 2025-381.9%−170.9
Q2 FY2025Jun 30, 2025-319.1%−276.4
Q1 FY2025Mar 31, 2025-223.0%−50.9
Q4 FY2024Dec 31, 2024-216.0%−49.1
Q3 FY2024Sep 30, 2024-211.0%+205.8
Q2 FY2024Jun 30, 2024-42.7%+620.6
Q1 FY2024Mar 31, 2024-172.1%+1191.7
Q4 FY2023Dec 31, 2023-167.0%+1679.8
Q3 FY2023Sep 30, 2023-416.8%+2447.8
Q2 FY2023Jun 30, 2023-663.3%+809.8
Q1 FY2023Mar 31, 2023-1363.8%−115.2
Q4 FY2022Dec 31, 2022-1846.8%+5777.0
Q3 FY2022Sep 30, 2022-2864.6%−1139.0
Q2 FY2022Jun 30, 2022-1473.1%+5006.7
Q1 FY2022Mar 31, 2022-1248.6%–
Q4 FY2021Dec 31, 2021-7623.8%–
Q3 FY2021Sep 30, 2021-1725.6%–
Q2 FY2021Jun 30, 2021-6479.8%–

More ProQR Therapeutics figures

See a number that looks wrong?